Key facts
- This page summarizes Eric Easom's Form 4 filing for AN2 Therapeutics, Inc. (ANTX).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 14 Nov 2022, 19:48.
Eric Easom - 10 Nov 2022 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- ANTX
- Reported as of
- 10 Nov 2022
- Net transaction value
- -$67,974
- SEC form
- 4
- Accepted by SEC
- 14 Nov 2022, 19:48:04 UTC
- Prior SEC filing
- 09 Nov 2022
- Next SEC filing
- 24 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lucy Day, Attorney-in-Fact for Eric Easom
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Easom filed Form 4 for AN2 Therapeutics, Inc. (ANTX) on 14 Nov 2022.
Change
- Previous filing in this sequence was filed on 09 Nov 2022.
- Current net transaction value: -$67,974.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ANTX
transaction
Common Stock
Sale
- Transaction value
- $67,628
- Shares
- -4,413
- Change %
- -47%
- Price
- $15.32
- Shares after
- 4,930
- Date
- 10 Nov 2022
- Ownership
- Direct
- Footnotes
- F1, F2
ANTX
transaction
Common Stock
Sale
- Transaction value
- $346
- Shares
- -23
- Change %
- -0.47%
- Price
- $15.04
- Shares after
- 4,907
- Date
- 14 Nov 2022
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
Footnote F2
Price reported is a weighted-average sales price. The shares were sold at prices ranging from $15.00 to $15.85. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.